Li Xuelong, Gong Wenjing, Tang Kun, Kang Jingwen, Song Fubo, Wang Yan
Department of Clinical Nutrition, Yantai Yuhuangding Hospital, Yantai, 264000, Shandong, China.
Department of Internal Medicine, Yantai Yuhuangding Hospital, Yantai, 264000, Shandong, China.
Sci Rep. 2025 Mar 24;15(1):10063. doi: 10.1038/s41598-025-95005-x.
The role of gut microbiota in cancer treatment research is receiving increasing attention. This study aims to evaluate the oral nutritional supplementation combined with probiotics on the liver function and intestinal microflora of lung cancer chemotherapy patients. An evaluation was conducted involving 113 patients with lung cancer, who were given routine hospitalization diet and oral nutrition supplement (ONS). The intervention group received probiotic supplementation, while the control group received placebo. It lasted for 21 days. The primary endpoint was the changes in liver function and intestinal microflora. Secondary endpoints included nutrition and immune status, and blood lipids. Compared with the control group, there were differences in the serum levels of ALT, AST, endotoxin and the amount of gut microbiota in the intervention group (P < 0.05). However, no significant changes were found in nutrition, immune, and the blood lipids status. ONS combined with probiotics could improve the liver function and gut microbiota status of lung cancer chemotherapy patients. We speculate that this may be due to the role of supplementing probiotics in regulating the gut-liver axis.
肠道微生物群在癌症治疗研究中的作用正受到越来越多的关注。本研究旨在评估口服营养补充剂联合益生菌对肺癌化疗患者肝功能和肠道微生物群的影响。对113例肺癌患者进行了评估，这些患者接受常规住院饮食和口服营养补充剂（ONS）。干预组接受益生菌补充，而对照组接受安慰剂。持续21天。主要终点是肝功能和肠道微生物群的变化。次要终点包括营养和免疫状况以及血脂。与对照组相比，干预组血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、内毒素水平及肠道微生物群数量存在差异（P<0.05）。然而，营养、免疫和血脂状况未发现显著变化。ONS联合益生菌可改善肺癌化疗患者的肝功能和肠道微生物群状况。我们推测这可能是由于补充益生菌在调节肠-肝轴中发挥的作用。
